Roche data at ESMO 2019 on first-line med for non-small cell lung cancer

• New real-world data from the Flatiron database supports clinical benefits of Alecensa® (alectinib) across time to treatment discontinuation, real-world progression free survival and overall survival
• Final PFS and updated data from the pivotal Phase III ALEX study reinforces efficacy of Alecensa in first-line ALK-positive non-small cell lung cancer and shows progression free survival of nearly three years

Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new data at the European Society for Medical Oncology (ESMO) 2019 congress, announcing the results of a number of studies in patients receiving Alecensa® (alectinib) for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

“The data presented at ESMO this year further demonstrate the well-established benefits of Alecensa, and confirm its use as the standard of care for newly diagnosed advanced or metastatic ALK-positive lung cancer patients,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “The positive results from our real-world data study further support the benefits we have seen from our Phase III clinical studies.”

https://www.marketscreener.com/ROCHE-HOLDING-LTD-9364975/news/Roche-to-present-new-and-updated-data-at-ESMO-2019-reinforcing-the-use-of-Alecensa-in-the-first-line-29273822/